Correspondence on "ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)" by Miller et al
- PMID: 34906520
- DOI: 10.1016/j.gim.2021.10.020
Correspondence on "ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)" by Miller et al
Conflict of interest statement
Conflict of Interest J.S.W. has consulted for MyoKardia, Inc and Foresite Labs. D.P.O. has consulted for Bayer. All other authors declare no conflicts of interest.
Comment in
-
Response to McGurk et al.Genet Med. 2022 Mar;24(3):747-748. doi: 10.1016/j.gim.2021.10.021. Epub 2021 Nov 30. Genet Med. 2022. PMID: 34906521 No abstract available.
Comment on
-
ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG).Genet Med. 2021 Aug;23(8):1381-1390. doi: 10.1038/s41436-021-01172-3. Epub 2021 May 20. Genet Med. 2021. PMID: 34012068 No abstract available.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources